In reply to the letter from Hallett et al. (1) , we would like to clarify some subtleties. The unexpected finding of our paper (2) was that degeneration of the striatal component of grafts resembled, in many ways, the neural degeneration in the striatum of patients with Huntington's disease (HD). These similarities include that (i) grafted projection neurons degenerated preferentially in comparison to interneurons, which recapitulates the pattern of neural degeneration in HD; (ii) cells degenerated at least in part via apoptotic mechanisms; (iii) cells had a markedly degenerated appearance in comparison with our earlier report at 18 months after transplantation in a patient with HD using identical techniques; and (iv) mechanisms of neural degeneration via targeted microglial infiltration and glutamate neurotoxicity of projection neurons were postulated based on supporting findings in our new report. Our grafts did not express the mutated huntingtin protein, as would be anticipated for genetically unrelated cells. It is for this reason that the title of our paper identified the process as ''disease-like'' rather than ''disease-specific'' changes.
Our findings support the role of glutamate excitotoxicity and microglial activation specifically as contributing factors to the degeneration of the striatal components of our grafts. Other mechanisms contributing to graft degeneration may also play a role. We found that graft survival was significantly more robust in the putamen than the caudate, which may reflect a poor transplant environment in the caudate of patients with HD. HD pathology in general is first manifested pathologically in the caudate. The rate of degeneration in the grafts was accelerated in comparison to the host, possibly due to concomitant allograft inflammatory responses (3, 4) . However, such immunological differences have never been documented to eliminate grafts in more than 10 publications using identical methods in Parkinson's disease (PD) patients (3, 5-7). The patterns of degeneration seen in the grafts may also be due to stressors, as Hallett et al. (1) discussed. However, they cited effects of stressors in two unrelated rodent models, which may not be relevant. It is not known if such stressors are clinically relevant in HD as well and may have contributed in part to our observations. Therefore, although other mechanisms may contribute to the findings, it is not our impression that they are primarily responsible for the results observed in our study.
Degeneration of grafts of the magnitude observed in this study, using multiple genetically unrelated donors transplanted in numerous needle tracks bilaterally, has never been observed in more than 10 autopsies of PD patients using identical techniques. In PD, only 2-8% of transplanted dopaminergic neurons showed Lewy-body inclusions (5-7), and two of the patients had prolonged benefits lasting more than a decade (5) . This suggests that additional mechanisms globally affect all transplants in HD specifically, using our methods. The volume of grafts in our PD and HD patients was quite similar. Stem cells may improve the dosing required for cell therapies.
Our results are part of the progressive understanding of cell therapies and brain repair. It is our hope that these findings will stimulate research into new ways to improve graft survival and further understand the mechanisms involved in HD. 
